{"id":93899,"topic":"peptides","source":"观点网","title":"诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65% - 观点网","url":"https://www.guandian.cn/m/show/608749","url_hash":"c5827f9da282235fa35dc777d48f9005ea38ec7d","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiTkFVX3lxTFAzVTFVa0daSVlCZEFEdU5aQUxObFBNelBMYlJCalEzNWZVdHRseUNfUHo5cGhubXlYSW4zc21VZ3NHajRhZGtFZW5TQW56UQ?oc=5\" target=\"_blank\">诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65%</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">观点网</font>","content":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死、非致死性卒中、全因死亡组成的复合事件）风险25%，显著降低全因死亡风险65%。","image_url":null,"lang":"zh","published_at":"2026-09-30T02:27:33+00:00","fetched_at":"2026-10-01T01:15:14+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死…","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.guandian.cn/m/show/608749","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 260 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":260,"summary_length":221,"usable_text_length":260,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":260,"summary_length":221}},"news_item":{"id":93899,"canonical_url":"https://www.guandian.cn/m/show/608749","source_url":"https://www.guandian.cn/m/show/608749","title":"诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65% - 观点网","source_name":"观点网","author":null,"published_at":"2026-09-30T02:27:33+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiTkFVX3lxTFAzVTFVa0daSVlCZEFEdU5aQUxObFBNelBMYlJCalEzNWZVdHRseUNfUHo5cGhubXlYSW4zc21VZ3NHajRhZGtFZW5TQW56UQ?oc=5\" target=\"_blank\">诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65%</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">观点网</font>","full_text":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死、非致死性卒中、全因死亡组成的复合事件）风险25%，显著降低全因死亡风险65%。","excerpt":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死…","extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 260 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/608749","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 260 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":260,"summary_length":221,"usable_text_length":260,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":260,"summary_length":221}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65% - 观点网","url":"https://www.guandian.cn/m/show/608749","summary":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死…","source":"观点网","date":"2026-09-30T02:27:33+00:00","content":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死、非致死性卒中、全因死亡组成的复合事件）风险25%，显著降低全因死亡风险65%。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/608749","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 260 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 260 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":260,"summary_length":221,"usable_text_length":260,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":260,"summary_length":221}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/93899","export_markdown":"/api/items/93899/export?format=markdown","export_json":"/api/items/93899/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/608749"},"formats":{"full":{"id":93899,"title":"诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65% - 观点网","url":"https://www.guandian.cn/m/show/608749","source":"观点网","author":null,"published_at":"2026-09-30T02:27:33+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死…","full_text":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死、非致死性卒中、全因死亡组成的复合事件）风险25%，显著降低全因死亡风险65%。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 260 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/608749","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 260 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":260,"summary_length":221,"usable_text_length":260,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":260,"summary_length":221}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 260 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":260,"summary_length":221,"usable_text_length":260,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":260,"summary_length":221}},"actions":{"read":"/item/93899","export_markdown":"/api/items/93899/export?format=markdown","export_json":"/api/items/93899/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/608749"}},"digest":{"id":93899,"title":"诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65% - 观点网","url":"https://www.guandian.cn/m/show/608749","source":"观点网","topic":"peptides","published_at":"2026-09-30T02:27:33+00:00","excerpt":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。 研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。 据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。 在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死…","quality_bucket":"medium","quality_reason":"Medium confidence: short full text extraction produced 260 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65% - 观点网","subtitle":"观点网 · 2026-09-30","summary":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。 研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。 据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。…","badges":["quality:medium"],"links":{"read":"/item/93899","original":"https://www.guandian.cn/m/show/608749","diagnose":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/608749"},"quality_warning":null},"export":{"title":"诺和诺德中国司美格鲁肽真实世界研究登EASD 全因死亡风险降65% - 观点网","url":"https://www.guandian.cn/m/show/608749","summary":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死…","source":"观点网","date":"2026-09-30T02:27:33+00:00","content":"观点网讯：9月29日，由诺和诺德中国发起的SPOTLIGHT真实世界研究结果在第62届欧洲糖尿病研究协会（EASD）年会上正式公布。\n研究结果显示，在中国2型糖尿病（T2D）患者中，司美格鲁肽注射液可显著降低心肾事件和全因死亡风险。\n据悉，SPOTLIGHT是一项基于中国天津地区电子健康档案数据库开展的回顾性真实世界研究。\n在中位1.9年的随访期间，与非司美格鲁肽组相比，司美格鲁肽组显著降低中国T2D患者3P-MACE（非致死性心肌梗死、非致死性卒中、全因死亡组成的复合事件）风险25%，显著降低全因死亡风险65%。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//www.guandian.cn/m/show/608749","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 260 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 260 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":260,"summary_length":221,"usable_text_length":260,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":260,"summary_length":221}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}